November 2013

Breast Cancer Care at UNC Lineberger

 

The UNC Breast Center takes a multidisciplinary approach to diagnosing and treating patients with breast cancer. The core values of the UNC Breast Center are ensuring clinical excellence across all disciplines and the creation of knowledge through a cross-disciplinary relationship with scientists and researchers. To complement our services, the UNC Lineberger Comprehensive Cancer Center operates a Brain Metastases Specialty Clinic, a Geriatric Oncology Clinic and a Cancer Genetics Clinic.

To make a referral, call 919-966-0000. For additional information, visit the, visit the program's website.

Walking program reduces joint stiffness in older breast cancer survivors on aromatase inhibitor therapy

New research from Kirsten A. Nyrop, PhD, Research Associate at the Thurston Arthritis Research Center shows that a moderate-intensity self-directed walking program is feasible for older breast cancer patients on aromatase inhibitor (AI) therapy and almost doubled the total time of walking per week over a 6 week period.

 

The study examined breast cancer survivors over age 65 who were currently on AI therapy and who had self-reported joint pain and stiffness. The participants engaged in an evidence-based self-directed 6-week physical activity program for adults with arthritis using the Arthritis Foundation's Walk With Ease (WWE) program.

Joint pain, stiffness, and fatigue decreased, and the walking program was perceived as informative and motivational. These data are promising and the WWE intervention warrants testing in a larger randomized trial of breast cancer survivors on AI therapy.

For more information about the study, click here.

Carolina Breast Cancer Study enrolls record 3,000 participants

Researchers leading the Carolina Breast Cancer Study (CBCS) have enrolled the 3,000th participant for the study's third phase, making it the largest-ever population-based study of breast cancer in North Carolina and one of the largest in the world. This milestone completes enrollment and initiates the five year follow-up.

Launched in 1993, the study aims to improve understanding of breast cancer, including why the disease's fatality rate is higher in African-American women. Phase III will focus specifically on how treatment decisions, access to care, and financial or geographic barriers impact breast cancer outcomes and whether these outcomes are predictable or altered by genetic breast cancer subtypes.

Participants were identified from a list of newly diagnosed breast cancer patients provided by the North Carolina Central Cancer Registry (NCCCR), which identifies and registers all new cancer diagnoses in the state. Participants were then selected through a scientifically sound, randomized process, and physicians were notified of the study's intent to contact their patient.

This recent enrollment milestone puts the total number of CBCS participants at over 7,300. 

CBCS is conducted by UNC Gillings School of Global Public Health and UNC School of Medicine faculty with funding from the University Cancer Research Fund, the National Cancer Institute, UNC Breast SPORE and Susan G. Komen for the CureĀ®.

Featured clinical trials from the UNC Breast Center

Click here to download a flow chart of open clinical trials for metastatic breast cancer patients

Featured clinical trials from the UNC Brain Metastasis Specialty Clinic

2B3-101-CR-001: An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma (PI: Anders)

N107C: A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease (PI: Zagar).

RTOG0933: A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases (PI: Zagar)

LCCC1024: A Phase I Study of BKM120 or BEZ235 and Capecitabine in Patients with Metastatic Breast Cancer (PI: Dees)

LCCC1025: A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases (PI: Anders)

DFCI10-107: Prospective Study of Neurocognitive Outcomes following Whole Brain Radiotherapy for Newly Diagnosed Brain Metastasis in Breast Cancer Patients (PI: Anders)

 

 

  Find us on Facebook  |   Follow us on Twitter  |   Watch us on YouTube

UNC Lineberger   N.C. Cancer Hospital   Clinical Trials   Clinical Programs   Comprehensive Cancer Support

 

For questions about all clinical trials at UNC, contact the UNC Lineberger Protocol Office at 919-966-4432 or (toll-free) 1-877-668-0683. For questions about clinical trials offered at other sites, contact the UNC Cancer Network at 919-966-7359 or (toll-free) 1-877-668-0683.

 

To make an appointment at the N.C. Cancer Hospital for one of your patients, visit our web page for referring physicians. You may also contact the Carolina Consultation Center at 1-800-862-6264.